Unexpected Synergy Reveals New Therapeutic Strategy in SCLC

Benjamin J. Drapkin; Anna F. Farago

doi:10.1016/j.tips.2019.03.005

Unexpected Synergy Reveals New Therapeutic Strategy in SCLC

Benjamin J. Drapkin, Anna F. Farago

Research output: Contribution to journal › Short survey › peer-review

15 Scopus citations

Abstract

DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.

Original language	English (US)
Pages (from-to)	295-297
Number of pages	3
Journal	Trends in Pharmacological Sciences
Volume	40
Issue number	5
DOIs	https://doi.org/10.1016/j.tips.2019.03.005
State	Published - May 2019
Externally published	Yes

Keywords

checkpoint kinase 1 inhibitor
immune checkpoint blockade
PARP inhibitor
PD-1
PD-L1
SCLC

ASJC Scopus subject areas

Toxicology
Pharmacology

Access to Document

10.1016/j.tips.2019.03.005

Cite this

@article{708b714ed37a4d95b0c7a49d8f2b78ac,

title = "Unexpected Synergy Reveals New Therapeutic Strategy in SCLC",

abstract = "DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.",

keywords = "checkpoint kinase 1 inhibitor, immune checkpoint blockade, PARP inhibitor, PD-1, PD-L1, SCLC",

author = "Drapkin, {Benjamin J.} and Farago, {Anna F.}",

year = "2019",

month = may,

doi = "10.1016/j.tips.2019.03.005",

language = "English (US)",

volume = "40",

pages = "295--297",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Unexpected Synergy Reveals New Therapeutic Strategy in SCLC

AU - Drapkin, Benjamin J.

AU - Farago, Anna F.

PY - 2019/5

Y1 - 2019/5

N2 - DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.

AB - DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.

KW - checkpoint kinase 1 inhibitor

KW - immune checkpoint blockade

KW - PARP inhibitor

KW - PD-1

KW - PD-L1

KW - SCLC

UR - http://www.scopus.com/inward/record.url?scp=85063884272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063884272&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2019.03.005

DO - 10.1016/j.tips.2019.03.005

M3 - Short survey

C2 - 30975441

AN - SCOPUS:85063884272

SN - 0165-6147

VL - 40

SP - 295

EP - 297

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 5

ER -

Unexpected Synergy Reveals New Therapeutic Strategy in SCLC

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this